GlassScriptPhysician profile
Debra J Blair
NPI 1568454973
$9,207.84
in general payments reported to CMS, 2019-2025
29 companies · $1,660 in 2025
The $1,660 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,650 · 2022: $2,109 · 2023: $2,231 · 2024: $1,558 · 2025: $1,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,253 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,252.56 |
| Education | $196.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,318.85 | 2021-2025 | |
| Janssen Biotech, INC. | $1,569.52 | 2021-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $1,227.63 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $602.97 | 2021-2025 | Trulance, Xifaxan |
| Ironwood Pharmaceuticals, INC | $455.49 | 2021-2024 | Linzess |
| Ardelyx, INC. | $435.56 | 2022-2025 | Ibsrela |
| Celgene Corporation | $395.87 | 2021-2023 | Zeposia |
| Pfizer INC. | $337.61 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $294.67 | 2021-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $240.51 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $199.46 | 2021-2024 | Rebyota, Clenpiq |
| Braintree Laboratories, INC. | $140.78 | 2021-2025 | Suflave, Sutab |
| Genzyme Corporation | $137.86 | 2022-2025 | |
| Daiichi Sankyo INC. | $110.15 | 2021-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $101.11 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $94.25 | 2023-2025 | Wegovy |
| Madrigal Pharmaceuticals | $68.98 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $64.18 | 2022-2023 | |
| Lilly USA, LLC | $60.43 | 2025 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.63 | 2023-2024 | Cyltezo |
| Qol Medical, LLC | $53.05 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $49.39 | 2023-2024 | Dupixent |
| Redhill Biopharma INC. | $42.55 | 2021 | |
| Gilead Sciences, INC. | $42.41 | 2024 | |
| Amgen INC. | $23.93 | 2023 | Amjevita, Avsola |
| Aimmune Therapeutics, INC. | $23.59 | 2024 | |
| Fujifilm Healthcare Americas Corporation | $21.13 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.72 | 2025 | |
| Sandoz INC. | $19.56 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Blair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.